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The National Cancer Institute (NCI) sponsored the NCI Thy-
roid Fine-Needle Aspiration (FNA) State of the Science Confer-
ence on October 22–23, 2007 in Bethesda, MD. The 2-day
meeting was accompanied by a permanent informational web-
site and several on-line discussions between May 1 and De-
cember 15, 2007 (http://thyroidfna.cancer.gov). This document
summarizes the indications for performing an FNA of a nodule
discovered by physical examination or an imaging study; the
indications for using ultrasound versus palpation for guidance
when performing a thyroid FNA; the issues surrounding
informed consent for thyroid FNA; and the information
required on a requisition form that accompanies a thyroid
FNA specimen. (http://thyroidfna.cancer.gov/pages/info/agenda/)
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The authors of this document comprised Committee I of
the NCI Thyroid Fine-Needle Aspiration (FNA) State of
the Science Conference. The charge of this committee
was to evaluate the state of the science of thyroid FNA
with regard to the indications for performing a thyroid
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FNA and the prethyroid FNA requirements. This is a
summary of the ‘‘Review and Conclusions’’ of the subject
matter that this committee analyzed based on literature
reviews limited to English language publications dating
back to 1995 using PubMed as the search engine, with
key words determined by the committee members; online
forum discussions (http://thyroidfna.cancer.gov/forums/
default.aspx); and formal interdisciplinary discussions
held at the October 2007 conference. This is not a ‘‘stand-
ards of practice’’ guideline, nor is it endorsed as such by
the National Cancer Institute.
Indications for Performing an FNA of a Thyroid
Nodule Discovered by Palpation
Every patient with a palpable thyroid nodule is a candi-
date for fine-needle aspiration (FNA) and should undergo
further evaluation to determine if an FNA is warranted.1–3
Thyroid nodules detected by palpation are usually at least
1.0 cm in dimension4,5 and are therefore potentially clini-
cally significant. Before a decision is made to perform an
FNA, a complete history should be obtained; a physical
examination directed to the thyroid gland and cervical
lymph nodes should be performed; and a serum thyrotro-
pin level (TSH) and thyroid ultrasound (US) should be
obtained.1,3,6–8
Significant history or physical examination findings that
increase the likelihood of malignancy include a family
history of thyroid cancer, prior head and neck or total
body irradiation, rapid growth of the nodule, a very firm
or hard nodule, hoarseness or vocal cord paralysis, ipsilat-
eral cervical lymphadenopathy, and fixation of the nodule
to surrounding tissues.1,3,6,9,10
Patients with a normal or elevated serum TSH level
should proceed to a thyroid US to determine if an FNA
needs to be performed (see section ‘‘Indications for Per-
forming an FNA of a Thyroid Nodule Discovered via
Imaging’’); those with a depressed serum TSH should
have a radionuclide thyroid scan, the results of which
should be correlated with the sonographic findings.1,3,6,7,11
Functioning thyroid nodules in the absence of significant
clinical findings do not require an FNA because the inci-
dence of malignancy is exceedingly low.12 A nodule that
appears either iso- or hypo-functioning on radionuclide
scan should be considered for FNA based on the US find-
ings (see section ‘‘Indications for Performing an FNA of
a Thyroid Nodule Discovered via Imaging’’).1–3
Contraindications to thyroid FNA are very few: an
uncooperative patient and a severe bleeding diathesis. In
such circumstances appropriate medical consultation
should be sought prior to the FNA.13–15 The most signifi-
cant (but extremely rare) complication of thyroid FNA,
limited to a few case reports and small series, is intrathyr-
oidal hemorrhage and acute upper airway obstruction.16
Extrapolating from recommendations for endoscopic US-
guided FNA, it is usually possible to perform an FNA on a
patient who is taking standard doses of aspirin, other non-
steroidal anti-inflammatory drugs (NSAIDS), or prophylac-
tic low molecular weight heparins (LMWH).3,14,17,18
Nevertheless, consideration should be given to stopping
LMWH at least 8 hour before the procedure.19 In patients
taking therapeutic doses of warfarin or heparin/LMWH,
performing a thyroid FNA is controversial but can be
done.18,19 There are no data on the safety of FNA in patients
taking anti-platelet medications like Plavix1 (clopidogrel
bisulfate). A reasonable approach is to stop the medication
for 3–5 days with agreement from the prescribing doctor. If
this cannot be done safely, an FNA may be performed using
the smallest needle possible and limiting the number of
passes performed. In this scenario, US guidance may be
preferable so that the surrounding small vessels can be
visualized and avoided.
Conclusions:
1. Before biopsying a patient with one or more thyroid
nodules discovered by palpation, a serum TSH level
should be measured and an US examination per-
formed.
2. If the serum TSH level is depressed, the findings of
a radionuclide thyroid scan should be correlated
with those of US examination. If the nodule of inter-
est is hot, an FNA is not indicated.
3. If the serum TSH is normal or elevated, an US ex-
amination should be performed to determine if sono-
graphic criteria for FNA are met (see section ‘‘Indi-
cations for Performing an FNA of a Thyroid Nodule
Discovered via Imaging’’). If so, the nodule should
be biopsied.
4. An FNA may be contraindicated if the patient is
uncooperative.
5. An FNA may be contraindicated if the patient has a
severe bleeding diathesis.
Indications for Performing an FNA of a
Thyroid Nodule Discovered via Imaging
A nodule not previously suspected or discovered clinically
but detected by an imaging study is considered an inci-
dental nodule (‘‘incidentaloma’’). Whether or not a nodule
has been detected clinically depends on the expertise of
the person performing the clinical examination (if one
was done), the size and mobility of the patient’s neck,
and the size and location of the nodule.
Incidentalomas detected by 18FDG-PET are unusual
(2–3% of all PET scans) but have a higher risk of cancer
(14–50%) compared to the background incidence.20–28 A
focal 18FDG-PET-avid thyroid nodule is much more
likely to be a primary thyroid cancer than metastatic dis-
ease to the thyroid, even in patients with an extrathyroidal
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malignancy. Many 18FDG-PET-avid lesions that are not
papillary cancer are follicular or Hurthle cell neoplasms.
Therefore, a focal nodule that is 18FDG-PET-avid is an
indication for FNA. This applies only to focal lesions.
Diffuse increased uptake on 18FDG-PET does not warrant
FNA unless thyroid sonography detects a discrete nodule.
All focal hot nodules detected on sestamibi scans and
confirmed by US to be a discrete nodule should undergo
FNA. Thyroid incidentalomas detected on sestamibi scans
have a high risk of cancer (22–66%).29–33 Many that are
not papillary cancer are follicular neoplasms.
Incidentalomas detected by US (such as carotid Dopp-
ler scans or scans done for parathyroid disease) have a
cancer risk of *10–15% (0–29%)34–46 and should
undergo dedicated thyroid sonographic evaluation.
Lesions with a maximum diameter greater than 1.0–1.5
cm should be considered for biopsy unless they are sim-
ple cysts or septated cysts with no solid elements. FNA
may also occasionally be replaced by periodic follow-up
for nodules of borderline size (between 1.0 and 1.5 cm in
maximum diameter) if they have sonographic features
that are strongly associated with benign cytology.
A nodule of any size with sonographically suspicious
features should also be considered for FNA. Sonographi-
cally suspicious features include:
 microcalcifications
 hypoechoic solid nodules
 irregular/lobulated margins
 intra-nodular vascularity
 nodal metastases (or signs of extracapsular spread)
This latter approach is controversial because it includes
patients with microcarcinomas, in whom a survival benefit
following an FNA diagnosis has not been documented.
Nevertheless, the American Thyroid Association,1 the
Academy of Clinical Thyroidologists,34 and a collabora-
tive effort of the American Association of Clinical Endo-
crinologists and the Associazione Medici Endocrinologi47
make this recommendation (Table I). There are several
reasons for this approach. A nodule that has suspicious
sonographic features may not be malignant. If the nodule
is benign by FNA, the patient can be reassured, and sub-
sequent follow-up can be less frequent. On the other
hand, if the FNA reveals that the nodule is malignant,
surgery is generally recommended. The natural history of
micropapillary carcinomas, however, is not well under-
stood. Most remain indolent, as implied by the 13% prev-
alence of micropapillary cancers in the United States at
autopsy examination.48 A minority follow a more aggres-
sive course; this subgroup might be identified by sono-
graphic evidence of lateral cervical node metastases,
tumor multifocality, extrathyroidal invasion, or cytopatho-
logic features that suggest a high-grade malignancy.49
The development and application of even more sensitive
and specific markers of aggressive potential (including
molecular and genetic markers) may one day facilitate tri-
age of patients with a microcarcinoma.
There are few direct data on the cancer risk of thy-
roid incidentalomas detected by computed tomography
(CT) or magnetic resonance imaging (MRI). They are
seen in at least 16% of patients evaluated by neck CT
or MRI.50 The risk of cancer in one study was predicted
at 10%, but it included only a limited number of
patients who went on to FNA.51 CT and MRI features
can not determine the risk of malignancy, except in
very advanced cases that are unlikely to be incidental.
Until more data are available, incidentalomas seen on
CT or MRI should undergo dedicated thyroid sono-
graphic evaluation. Any nodule with sonographically
suspicious features (see above) should be considered for
FNA. In addition, lesions that have a maximum diame-
Table I. Indications for Thyroid FNA: Recommendations of Professional Societies
ACT a ATAb AACE a SRUb
<10 mm <10 mm <10 mm <10 mm
FNA if clinical risk factors FNA if clinical risk factors or
suspicious US features
FNA if clinical risk factors or
suspicious US features
No recommendation
5–10 mm >10 mm
FNA if suspicious US features FNA if microcalcifications
10–20 mm >15 mm
FNA most nodules FNA if solid with coarse calcifications
May defer FNA if benign US
features
>20 mm >10–15 mm >10 mm >20 mm
FNA all FNA all FNA all FNA if mixed solid & cystic or cystic
with mural nodule
ACT, Academy of Clinical Thyroidologists; ATA, American Thyroid Association; AACE, American Association of Clinical Endocrinologists; SRU,
Society of Radiologists in Ultrasound.38
aNodule size not specified as maximum or mean.
bNodule size refers to maximum dimension.
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ter greater than 1.0–1.5 cm should also be considered
for FNA (see above).
As discussed in section ‘‘Indications for Performing an
FNA of a Thyroid Nodule Discovered by Palpation,’’ se-
rum TSH levels may influence the decision to perform an
FNA on an incidentaloma. Given the infrequency with
which TSH levels are depressed, the decision to perform
an FNA need not be delayed if the patient is undergoing
sonography and the results are not available.
It may not be feasible or advisable to perform an FNA
for all incidentalomas. There are too many, the costs and
strain on the medical system would be too great, and such
a practice would ultimately lead to needless surgery on
many benign lesions. The goal in dealing with incidenta-
lomas is to avoid FNA as best possible for nodules likely
to be benign, while maximizing the number of malignant
nodules that are diagnosed. The consensus in the literature
and among professional societies specializing in thyroid dis-
eases is that incidentalomas should undergo sonography and
only those that have suspicious sonographic features, exceed
a certain size (1.0–1.5 cm), or have clinical risk factors
should undergo FNA. Given the imperfect ability of clinical
factors to predict the risk of cancer, and the unavoidable
overlap in sonographic features between benign and malig-
nant nodules, any recommendation will result in some
missed cancers and some FNAs of benign lesions.
Conclusions:
1. All focal 18FDG-PET-avid lesions should undergo FNA.
2. All hot nodules detected on sestamibi scans should
undergo FNA.
3. Incidentalomas detected by US should undergo a
dedicated thyroid sonographic evaluation.
4. Until more data are available, incidentalomas seen
on CT or MRI should undergo a dedicated thyroid
sonographic evaluation.
5. Any nodule with sonographically suspicious features
should be considered for FNA.
6. Lesions with a maximum diameter greater than 1.0–
1.5 cm should be considered for FNA.
Indications for Performing a Thyroid FNA
Using Palpation for Guidance
Palpation-guided FNA can be performed with high levels of
success in specific circumstances.2,52–54 In the setting of a
new, palpable thyroid enlargement without a definable nod-
ule on sonography, the decision to perform a biopsy or not
still depends to a large degree on the sonographic appear-
ance of the thyroid. If the thyroid is truly enlarged but is
normal in echogenicity and echotexture, then malignancy is
so unlikely that a biopsy is not necessary. On the other
hand, if the enlarged thyroid is hypoechoic and heterogene-
ous/coarsened, then the differential includes lymphocytic
thyroiditis (most commonly), and, rarely, uncommon
malignancies like lymphoma and anaplastic cancer, as well
as amyloid goiter. In such a case, an US-guided FNA may
be warranted depending on the size of the thyroid, the
degree of left to right asymmetry, other sonographic
features, or based on clinical or laboratory findings.
The benefits of palpation-guided FNA of thyroid nodules
are its reduced cost in comparison to US-guided FNA as
well as its logistical efficiency: the practitioner can perform
the procedure without an US machine or assistance from
other practitioners. In the evaluation of individual patients
with nodular disease, there are occasions when either pal-
pation or US-guided FNA of a thyroid nodule are reasona-
ble to perform. Published data from one study concluded
that US evaluation changes the management in 63% of
patients with palpable thyroid nodules.55 Thus, when thy-
roid nodules do not fulfill the criteria below, or when prac-
titioners trained in palpation-guided aspiration are not read-
ily available, US-guided FNA should be preferred.
Conclusions:
A palpation-guided FNA can be considered in the fol-
lowing scenarios:
1. A thyroid nodule > 1 cm in diameter has been con-
firmed via US examination of the thyroid. The sono-
graphic examination is important because physical
examination can be imprecise in determining nodule
size and its origin from the thyroid rather than adja-
cent tissues.56
2. The thyroid nodule is discrete and readily identified
on physical examination. Importantly, a diffuse or
asymmetric goiter without a discrete nodule on
physical examination should preclude palpation-
guided FNA in lieu of US-guided FNA.
3. The nodule is primarily solid (<25% cystic) on US
examination.57,58
4. The patient has no other head or neck illnesses or
prior head or neck surgery that may affect the thy-
roid anatomy.
5. A prior nondiagnostic biopsy of the nodule has not
occurred. In such cases, an US-guided FNA should
be performed.59
6. Obtaining US guidance for FNA is logistically diffi-
cult or not readily available.
Indications for Performing a Thyroid FNA
Using Ultrasound for Guidance
Ultrasound guidance for FNA of the thyroid gland is use-
ful in the combined evaluation of the thyroid nodule, as it
simultaneously allows detailed examination of the remain-
der of the thyroid gland, characterization of the nodule
(solid, cystic, well-circumscribed, irregular, calcifications,
vascularity, size, etc.), and accurate placement of the
aspiration needle in the nodule of interest. The advantages
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of US guidance include a decreased rate of insufficient or
inadequate cytology specimens in several studies in which
these were compared.52,53,60–62 US also allows sampling
from solid areas of partially cystic lesions, accounting for
some increase in adequacy.63 Not all studies show a dif-
ference in adequacy and accuracy, or show a difference
only for smaller lesions.60,64
US findings such as irregular margins, microcalcifica-
tions, intra-nodular vascularity, and the characteristics of
other occult thyroid nodules can be used by the clinician to
identify nodules at risk that should be sampled.45,65,66 US
guidance can also provide additional information for
patients who have had benign or nondiagnostic (i.e., insuffi-
cient cells/colloid) results from palpation-guided FNA.61,62
Re-evaluation of patients using US-guided FNA for those
with initially benign or nondiagnostic results can lead to the
reclassification of a substantial portion of patients and diag-
nose more cancers.61,62 Finally, there are US-specific find-
ings that can be used to inform the results of the US-guided
FNA (e.g., the benign sonographic appearance of a unilocu-
lar cyst explains why only cyst fluid was obtained by FNA).
Both palpation-localized and US-guided thyroid FNA
are widely practiced. Several studies have shown, how-
ever, that US-guided FNA is a more sensitive technique
than palpation-guided assessment.53,60,67 Regardless of the
localization method utilized, high levels of operator train-
ing and experience are key determinants of successful
FNA procedures. (See accompanying article in this issue
by Ljung et al.)
Conclusions:
1. US guidance should be used to aspirate nodules that
are not palpable.
2. US guidance should be used to aspirate nodules that
have an appreciable (>25%) cystic component.
3. US guidance should be used if a prior aspiration
contained insufficient cells/colloid for interpretation.
4. US guidance for thyroid FNA may be used as an al-
ternative to palpation localization because it permits
the operator to:
(a) be certain that the nodule of interest is aspirated
by direct imaging,
(b) be sure that a discrete nodule is present before
aspiration, and
(c) avoid passing the needle into critical structures
in the neck.
The Informed Consent Form for Thyroid FNA
Informed consent is the communication process between
a patient and physician that results in the patient’s agree-
ment to undergo a particular procedure or treatment.68–74
For the purposes of the following discussion, the proce-
dure is a thyroid FNA.75
The principle of informed consent is rooted in medical
ethics,76 codified as a legal principle,77 and based on the
assertion that a competent person has the right to determine
what is done to her or him.68–74 In the informed consent pro-
cess, the physician informs a patient about the risks and ben-
efits of a proposed therapy or procedure and allows the
patient to decide if the therapy or procedure should be under-
taken.78 Informed consent in the research setting differs con-
siderably from informed consent in a clinical context.79
In reality, all medical care, including the procuring of
all laboratory tests, requires informal informed consent,
except when the patient is incompetent to make a deci-
sion or gives up the right to provide it.68–74 Formal pro-
cedures of obtaining consent, such as the signing of a
consent form, following the exchange of information and
a patient-physician communication, are only undertaken
in some circumstance, such as prior to major invasive
procedures or surgery.68,80,81 Legislation regulating the
conditions under which consent must be obtained vary
greatly by state.68,72,73 Thus, providers (e.g., pathologists,
radiologists, surgeons, endocrinologists, etc.) who per-
form FNA need to design informed consent policies and
forms based on state regulations. In essence, there is a
lack of standardization of national informed consent
policy that determines exactly when and how informed
consent is obtained.
National organizations like the American Medical
Association (AMA) have provided general guidelines of
informed consent.73 The AMA recommends that the fol-
lowing be disclosed and discussed with the patient:
1. The patient’s diagnosis, if known;
2. The nature and purpose of a proposed treatment or
procedure;
3. The risks and benefits of a proposed treatment or
procedure;
4. Alternative options (regardless of their cost or the
extent to which these options are covered by health
insurance);
5. The risks and benefits of the alternative treatment or
procedure;
6. The risks and benefits of not receiving or under-
going a treatment or procedure.73
The AMA Code of Medical Ethics establishes informed
consent as an ethical obligation of physicians.73 Failure to
obtain adequate informed consent renders a physician
liable for negligence or battery and constitutes medical
malpractice.68
Although it has been suggested that improved
informed consent policies could result in improvements
in the patient-physician relationship, patient compliance,
patient trust of the healthcare system, and patient safety
(by providing information that could reduce medical
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error),82 this hypothesis has not been definitively
proved.
Many informed consent procedures are incomplete.68,69
In addition, less than 50% of the population understands
commonly used medical terms, resulting in a ‘‘health lit-
eracy’’ problem that limits patients in their attempts to
understand information.83–87 Several studies have focused
on insufficiencies in procedures to obtain informed con-
sent. Braddock et al. created a 3-tier evaluation procedure,
in which the completeness of the informed consent discus-
sions differed depending on the complexity of the
decision.70 Basic decisions (e.g., laboratory test ordering)
require discussing the clinical nature of the decision and
the evaluation of patient preferences. Intermediate deci-
sions (e.g., medication changes) require a moderate depth
of discussion and include adding a discussion of alternative
treatments, including the risks and benefits of these alterna-
tives and an assessment of patient understanding. Complex
decisions (e.g., undergoing an operative procedure) require
a discussion of the uncertainties associated with the proce-
dure, in addition to the components listed previously.
Providing written information, which is also discussed
during the informed consent process, may increase com-
prehension.88–91 This information, however, must be pro-
vided in a manner that is clearly understood by the
patient. Hooper et al. found that patients with a high
school education understand only 16% of all consent
forms.92,93 Jubelirer et al. reported that, in a study of
adult cancer patients, most had a reading level between
10th and 11th grade.84 Jubelirer et al. recommended that
consent forms be written at 3-grade levels below the high-
est level of education of the specific patient.84
For thyroid FNA, a consent form should be patient
friendly and written so that the patient fully understands the
procedure. Patient comprehension of thyroid FNA forms
has not been rigorously studied. Potential complications
should be listed on consent forms but written in a manner
understandable to all patients. Concepts such as false-nega-
tive and false-positive proportions need to be discussed and
written in terms that a patient understands; simply listing
such numbers likely would not benefit most patients.
Currently, informed consent is receiving a great deal of
attention, and a number of studies researching informed
consent have been performed. The Agency for Healthcare
Research and Quality (AHRQ) identified the challenge of
addressing shortcomings such as missed, incomplete or
not fully comprehended informed consent, as a significant
patient safety opportunity.68,71,82 Thus, informed consent
policies are evolving.
Conclusions:
1. Informed consent materials, including written docu-
ments, if used, should describe the FNA procedure
and potential risks and complications.
2. The possibility of a hematoma, the most frequently
occurring complication, should be mentioned.
3. Information should be presented in a manner to
facilitate patient understanding.
4. It might be useful to mention the possibility of a
noncontributory result.
5. Estimates of accuracy, such as false-negative or
false-positive proportions, are not mandatory and
should be considered only if the practitioner believes
they would facilitate patient comprehension.
Information Required on the Requisition
Form that Accompanies a Thyroid FNA
Federal regulations in the United States require that cer-
tain identifying information be provided to laboratories
with all specimens submitted for laboratory testing.94
These include:
 name and address of person requesting the test
 patient’s name or unique identifier
 patient’s gender
 patient’s age or date of birth
 name of the test to be performed
 specimen source
 date of specimen collection
 ‘‘any additional relevant information’’
The purpose of this discussion is to consider what
‘‘additional relevant information’’ a laboratory needs to
properly evaluate a thyroid FNA specimen.
With regard to the already required patient age, the
risk of malignancy may be greater in individuals that are
older (over age 60), and the risk is likely greater in
younger individuals (children, generally under age 20).
Risk is also increased in men.95–97 Papillary hyperplasias
that occur in children can be confused with papillary thy-
roid cancer.98
The location of the nodule (right vs. left; isthmus;
upper pole, mid-pole, lower pole, etc.) should be specified
on the requisition form to permit correlation with sono-
graphic findings and subsequent histopathologic examina-
tion (if applicable). Such identification is necessary beca-
use patients often present with multiple nodules (some
but not all of which may be biopsied), or they may de-
velop other nodules over time.
There is, at best, an imperfect correlation between the
size of a nodule and the likelihood of malignancy, but
larger nodules (>4 cm) may be associated with a higher
malignancy risk, and therefore size should be included.99
Benign cytologic changes that mimic malignancy, par-
ticularly papillary carcinoma, occur in some patients with
autoimmune (Hashimoto’s) thyroiditis. If not alerted to
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this history, a misdiagnosis can occur.100,101 Furthermore,
nuclear alterations may be seen in patients with a history
of I-131 therapy (for hyperthyroidism) or external radia-
tion.102–104 In some patient with Graves’ disease, an FNA
of a nodule may include pleomorphic cells from the
extra-nodular Graves’ thyroid parenchyma that can be a
pitfall in cytologic interpretation.105
It is important to note a personal history of malignancy
because metastatic tumors to the thyroid can mimic the
appearance of a primary thyroid neoplasm. Metastatic re-
nal cell carcinoma mimics a follicular neoplasm; mela-
noma can mimic medullary carcinoma; metastatic lung
cancer can mimic anaplastic carcinoma of the thyroid.
Cytologists should be alerted to the possibility of a meta-
static tumor in any patient with a history of malignancy.
Approximately 15% of medullary thyroid cancers are
familial (familial MTC or MEN2a or 2b). Knowledge of
family history can alert the pathologist to the possibility
of medullary carcinoma. In addition, recent data show
that papillary thyroid cancer can also be familial,106 and
thus knowledge of such family history can alert the pa-
thologist to consider papillary carcinoma.
The following information can be useful to the cytolo-
gist but is considered optional on the requisition form.
 Prior FNA. Morphologic alterations due to a prior
FNA can affect cytologic interpretation.107
 Concurrent levothyroxine therapy. Levothyroxine
(LT4) use can alter follicular cell morphology. Such
altered morphology can be encountered in an FNA
obtained because of nodule growth while a patient is
taking LT4. Nodules that yield a more cellular be-
nign specimen may demonstrate more colloid and de-
generative changes after LT4 therapy.108
 TSH level. If a patient has Hashimoto’s hypothyroid-
ism or Graves’ disease, cytologic findings can be
affected. A lower serum TSH level is also associated
with a lower risk of thyroid cancer.96
 Results of ultrasound examination
 US characteristics of the nodule
 US characteristics of surrounding extra-nodular
thyroid parenchyma
 presence of other nodules
 location of nodule
US characteristics associated with malignancy include
microcalcifications, hypoechogenicity, irregular margins,
and increased vascularity.45 Predominantly cystic nodules
may be less likely to be malignant.109 US imaging of the
surrounding extra-nodular thyroid may indicate that
Hashimoto’s (lymphocytic) thyroiditis is present, which,
as noted above, can cause benign cytologic changes that
mimic malignancy. Although the risk of cancer for an
individual patient is the same whether he/she has a single
or multiple nodules, the risk of malignancy per nodule is
lower if multiple nodules are present.109 The lower para-
thyroid glands may be contiguous to the thyroid at its
lower poles. Therefore, what is imaged as a lower pole
hypoechoic thyroid nodule may be a parathyroid gland.
 Results of nuclear medicine imaging studies (func-
tioning or not functioning). In general, a nodule that
functions on an I123 scan should not undergo
FNA.38,47,110
Conclusions:
At a minimum, the following data should appear on the
requisition form that accompanies a thyroid FNA to the
laboratory:
1. Usual required data for laboratory test submission
(see above)
2. Location of the nodule
3. Size of the nodule
4. History of hypothyroidism, autoimmune thyroiditis,
or a positive test for antithyroid antibodies
5. History of Graves’ disease
6. History of I131 or external radiation therapy
7. Personal history of cancer
8. Family history of thyroid cancer
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